Financials
Financial year 2025
Lansinoh Laboratories Benelux from Herentals, company number BE0630939468, closed financial year 2025 with a result of € 472,688 after tax. For that financial year Lansinoh Laboratories Benelux recorded a gross margin of € 887,520 and equity of € 1.6 million. Compared with financial year 2024, the result moved from € 193,701 to € 472,688. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 17, 2026.
€ 1.6 million
▼ 32% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 472,688
▲ 144% vs 2024
Profit after tax over the fiscal year.
€ 1.9 million
▲ 105% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 1.2 million paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
2.9
▼ 0.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 223,637
▲ 1% vs 2024
€ 77,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,204
▼ 29% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 212,096
▲ 19% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 95,748
▲ 12% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 471,258 | € 415,834 | € 587,137 | € 887,520 | ▲ 51% |
| Profit after taxes | € 132,732 | € 158,756 | € 193,701 | € 472,688 | ▲ 144% |
| Equity | € 1,955,645 | € 2,114,401 | € 2,308,102 | € 1,580,790 | ▼ 32% |
| Total debts | € 851,321 | € 457,418 | € 276,464 | € 1,526,523 | ▲ € 1.3 million |
| Cash | € 461,540 | € 604,312 | € 911,174 | € 1,868,350 | ▲ 105% |
| Retained profit | € 1,893,645 | € 2,052,401 | € 2,246,102 | € 1,518,790 | ▼ 32% |
| Dividend | € 0 | € 0 | € 0 | € 1,200,000 | |
| Balance sheet total | € 2,806,966 | € 2,571,819 | € 2,584,566 | € 3,107,313 | ▲ 20% |
| Employees (FTE) | 2.3 | 2.8 | 3 | 2.9 | ▼ 0.1 |
By gross margin, Lansinoh Laboratories Benelux ranks 35th of 155 companies with main activity “Groothandel in farmaceutische en medische artikelen” in the province of Antwerp that publish figures (fiscal year 2025).
Key figures of Lansinoh Laboratories Benelux, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about Lansinoh Laboratories Benelux the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to Lansinoh Laboratories Benelux?
What happened at Lansinoh Laboratories Benelux in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Vanessa Cook stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 472,688 (▲ 144% vs 2024). Source: NBB ↗
- Julie Talbot became a director. NBB
- Kevin Vyse-Peacock stepped down as director. NBB
- Kevin Vyse-Peacock became a director. NBB
- Vanessa Cook became a director. NBB
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Herentals. KBO
In short
From € 132,732 profit in 2022 to € 472,688 profit in 2025.
Paid € 396,746 in corporate taxes since 2022.
Best year ever: 2025, with € 472,688 profit.
On average € 306,000 of value added per employee in 2025.
Management
Behind Lansinoh Laboratories Benelux is Julie Talbot. It owns 100% of Lansinoh Laboratories France SAS itself.
Directors
According to the 2025 annual accounts
Julie Talbot
Director
since 2026
Kevin Vyse-Peacock
Director
since 2024 · until 2026
Vanessa Cook
Managing director
since 2024 · until 2031
Establishments
Establishment units
Physical locations of this company
Diamantstraat (HRT) 8 box 383
2200 Herentals
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in the province of Antwerp
Same main activity (Groothandel in farmaceutische en medische artikelen), 309 active companies in the province of Antwerp, largest first.
€ 675.3 million revenue · 2025 · Beerse
€ 385.9 million revenue · 2025 · Mechelen
€ 184.4 million revenue · 2025 · Mechelen
€ 114.8 million revenue · 2025 · Geel
€ 113.3 million revenue · 2025 · Mechelen
European Distribution Center Motiva
€ 93.9 million revenue · 2025 · Wommelgem
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- LANSINOH LABORATORIES INC.(oprichter) 100%
- LANSINOH LABORATORIES DEVICE MANUFACTURING LIMITED(oprichter) 0%
Details
- Company number
- 0630.939.468
- VAT number
- BE 0630.939.468
- Registered office
- Diamantstraat (HRT) 8 bus 383, 2200 Herentals
- Names & denominations
- Lansinoh Laboratories Benelux
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 29 May 2015
- Peppol
- Active · Active since 24 Nov 2023
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Verhuur en lease van medisch en paramedisch materieel
Reparatie en onderhoud van andere apparatuur
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels